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ABSTRACT 
 
BACKGROUND 
 
Uterine evacuation (EVAC) and manual vacuum aspiration (MVA) are 
commonly performed minor gynaecological procedures, often being done on 
an out-patient basis.  These procedures are associated with pain, but the 
severity and extent of the pain experienced, especially in the post-procedure 
period, is not well studied. 
 
OBJECTIVES 
 
The aim of this study was to determine whether patients who underwent 
EVAC and MVA procedures, experienced pain postoperatively; and if so, to 
quantify the degree of pain experienced. These patients were at Chris Hani 
Baragwanath Academic Hospital (CHBAH).   
 
The objectives of this study were to determine whether patients (having 
undergone EVAC and MVA) experienced pain postoperatively, and to also 
determine the intensity of the pain.  Additionally, to ascertain whether patient 
age, gestational age or the duration of the procedure, had any impact on the 
pain experienced. 
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METHOD 
 
A sample of 53 patients were selected, presenting for EVAC and MVA at 
CHBAH.  There were 26 patients in the EVAC group and 27 in the MVA 
group.  Information was collected from patient interviews and their hospital 
files and subsequently recorded on data sheets.  Data collected on each data 
sheet included:  patient age, gestation, procedure (EVAC or MVA), reason for 
procedure, length/duration of procedure and analgesia received prior to and 
during the procedure. 
 
Pain was assessed at intervals of 10 minutes, 40 minutes, 2 hours and 3 
hours post-procedure.  This was achieved using a ratio, which was 
determined from a visual analogue scale (VAS).  Patients who had pain 
greater than 3/10 on the VAS score, received rescue analgesia in the form of 
diclofenac, 1mg/kg diluted in 250 ml of Ringer‘s lactate, over 30 minutes 
intravenously. 
 
RESULTS 
 
Patients in the MVA group experienced significantly more pain immediately 
postoperatively than the patients in the EVAC group.  However, there were no 
significant differences found in pain experienced between the two groups at 
40 minutes and thereafter.  
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CONCLUSION 
 
Patients undergoing EVAC do experience pain, but if multimodal analgesia is 
provided, the pain experienced is not significant.  Patients undergoing MVA  
experience significant pain post-procedure.  It is recommended that improved 
analgesia protocols should be instituted. 
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CHAPTER ONE - INTRODUCTION 
 
Manual vacuum aspiration (MVA) and uterine evacuation (EVAC) are 
common minor gynaecological procedures performed worldwide.  Indications 
include termination of pregnancy (TOP), management of miscarriage and 
molar pregnancy.  MVA is usually done under conscious sedation, with or 
without local anaesthesia, when the gestational age is less than 14 weeks and 
the patient is haemodynamically stable (i.e. not requiring initial resuscitation).  
(1)  EVAC procedures are usually done under general anaesthesia when the 
gestational age is more than 14 weeks and/or if any haemodynamic instability 
exists.  (2) 
 
Preventing postoperative pain is a very important aspect of the provision of 
anaesthetic care.  Providing optimal pain relief postoperatively ensures patient 
satisfaction, reduces complications and reduces length of hospital stay.  (3) 
 
The definition of pain according to the ―International Association for the Study 
for Pain‖ is:   
Pain is an unpleasant sensory and emotional experience associated with 
actual or potential tissue damage.  (4)   
 
This definition makes pain very difficult to measure.   
Nevertheless, it is important to quantify pain for various reasons:   
1. to give a sense of control to the patient 
2. to ensure that adequate pain control measures and protocols are used  
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3. to prevent chronic pain from developing.  (5) 
 
The visual analogue scale (VAS) is a well-studied tool for measuring both 
acute and chronic pain.  (5)  Figure 1.1 
 
No pain ------------------------------------Moderate  --------------------------- Most severe pain 
0                                                         5                                                   10 
 
 Figure 1.1 Visual analogue scale (6) 
 
Even though the procedure is brief;  lasting only 5–15 min, 97% of women 
experience pain during either EVAC or MVA.  (1) 
 
The pain experienced during EVAC and MVA is a combination of pain arising 
from cervical dilatation, and also arising from uterine contractions.  Pain 
sensation is transmitted via sensory and sympathetic pathways from the 
posterolateral aspect of the cervix to the lateral spinothalamic tracts of the 
spinal cord.  The various steps used during EVAC — such as clamping, 
traction and dilation of the cervical os, as well as curettage itself—can cause 
discomfort.  (7)  
 
Dalton et al found that anticipated pain negatively affected outcome regarding 
satisfaction and pain experienced during MVA.  (8)  Pain is worsened by 
anxiety, pre-procedure fearfulness and depression.  (8) 
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Patients may have different reasons for requiring a procedure such as EVAC 
or MVA.  Patients requesting a TOP may present with a different emotional 
burden when compared to patients presenting with a miscarriage following a 
desired pregnancy.  (2)  While this needs to be borne in mind, the nature of 
the procedure required is similar, and the question of postoperative pain is  a 
valid concern in both situations.   
 
Various modes of pain relief have been studied for short gynaecological 
procedures such as EVAC and MVA.  Treatment modalities studied have 
ranged from pre-operative paracetamol and codeine suppositories, to intra-
operative opioids for EVAC performed under general anaesthesia.   (9) (10) 
(11).   
 
The general practice for EVAC done under general anaesthesia at Chris Hani 
Baragwanath Academic Hospital (CHBAH), is to use a short acting opioid 
such as alfentanil during the procedure.  Other drugs used for analgesia intra-
operatively, include diclofenac and ketamine.  Postoperatively, patients 
usually receive a combination of oral paracetamol and non-steroidal anti-
inflammatory agents, eg. ibuprofen.   
 
Various methods of providing analgesia for MVA have been studied.  These 
include doing paracervical blocks and the use of simple analgesics (like 
diclofenac) with or without concious sedation.  A randomized controlled trial 
has shown that the use of local anaesthesia for paracervical block is not 
associated with a reduction in pain levels for MVA.  (1) (11)   
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The practice at CHBAH is to use a diclofenac 75 mg intramuscular injection 
(IMI) for MVA given 20 minutes pre-procedure. 
 
1.1  Problem statement 
 
While various studies have been done to determine the intraoperative efficacy 
of the use of various pain relief modalities for EVAC or MVA, no studies have 
been conducted investigating the degree of postoperative pain in these 
groups of patients.  It is thus unclear whether the pain experienced during the 
procedure continues into the postoperative period or not, and if it does 
continue, to what magnitude. 
 
1.2  Study aims and objectives 
1.2.1  Aims 
The aim of this study was to determine whether patients having undergone 
EVAC and MVA experienced pain postoperatively, and if so, to quantify the 
degree of pain experienced by these patients at CHBAH. 
1.2.2  Objectives 
 To determine whether patients having undergone EVAC experienced 
pain postoperatively. 
 To determine whether patients having undergone MVA experienced pain 
postoperatively. 
5 
 
 To describe the intensity of postoperative pain experienced by patients 
having undergone EVAC. 
 To describe the intensity of postoperative pain experienced by patients 
having undergone MVA. 
 To review whether patient age, gestational age or duration of the 
procedure had any impact on the pain experienced. 
 
1.3  Validity and reliability of data 
 
To ensure validity and reliability of data, data was collected by the principal 
investigator.  A translator was used for interviewing one of the patients. 
 
1.4  Study design 
 
This is a prospective observational study. 
 
1.5.  Ethical considerations 
1.5.1  Ethical clearance 
This study has been approved by the University of the Witwatersrand, Human 
Research Ethics Committee.  (Appendix A) 
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1.5.2  Post-Graduate approval 
The study has been approved by the Post-Graduate Committee of the 
University of the Witwatersrand, Faculty of Health Sciences. 
1.5.3  Site approval 
Permission to conduct this study has been granted by the Senior Clinical 
Executive at CHBAH.  (Appendix B) 
1.5.4  Patient consent 
Patients that met the selection criteria were invited to participate in the study 
before having the procedure done.  The aims of the study were explained as 
well as the risks and potential benefits.  Patients received an information 
sheet containing all details of the planned study.  (Appendix C)   
 
The information sheet explained the reason for the study, the patient‘s 
involvement in the study, the right to refuse to participate without 
repercussions to their care, and the right to withdraw from the study at any 
time.  A 24-hour contact number was supplied should they have required 
further information.  The printed information was provided in English. 
 
The researcher and a translator provided verbal information in a language that 
the patient could understand if they could not understand English, or were not 
able to read the document.  Written consent was obtained from all patients 
agreeing to participate.  (Appendix D)  
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1.5.5  Declaration of Helsinki 
This study has been structured in accordance with the Declaration of Helsinki. 
(last updated October 2008) 
 
1.6 Summary of methodology 
 
After permissions from the relevant authorities were granted, participants 
were identified, either: 
- in the gynaecology outpatient clinic awaiting MVA, or  
- in the ward or theatre reception area, awaiting EVAC at CHBAH.  
 
Participants matching the inclusion criteria were approached for inclusion into 
the study.   
 
Written informed consent was obtained preoperatively from patients without 
exclusion criteria.  The patients were made aware that their participation was 
voluntary, and that their results would be analysed by means of a numerical 
code system.  All information that would link their identity to the trial results 
would remain separate and confidential. 
 
Use of a medically knowledgeable translator was made if a language barrier 
was encountered, or if the patient requested that the information and consent 
forms be explained to them in a language of their choice.  
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The sample size was calculated assuming that a difference existed between 
the two groups of patients.  The total sample calculated initially was 100 
patients.  The confidence interval of 9.3 would provide a confidence level of 
95% for a population of 1000 patients. 
 
In June 2011 the protocol for managing patients for MVAs at CHBAH was 
changed.  These routine patients are no longer managed at CHBAH.  All 
routine MVA patients are now being managed at primary level clinics.  Only 
complicated cases are referred for management at CHBAH.  This change in 
protocol has almost completely eliminated the number of patients presenting 
for MVA or EVAC. 
 
At the time of the protocol change in June 2011, 53 patients had been 
enrolled in the study.  There were 26 patients in the EVAC group and 27 in 
the MVA group.  Information was collected from patient interviews and their 
hospital files, and recorded on a data sheet.  (Appendix E).   
 
Data collected on the data sheet included:  patient age, gestation, procedure 
(EVAC or MVA), reason for procedure (TOP or miscarriage), length/duration 
of procedure, and also analgesia received prior to the procedure.  The 
patient‘s name and hospital number were collected, but kept on a separate list 
to ensure confidentiality.  This entire procedure was followed in case any 
patient decided to withdraw from the study. 
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Pain was assessed at intervals of 10 minutes, 40 minutes, 2 hours and 3 
hours post-procedure.  This was achieved using a ratio, which was 
determined from a VAS.  (Appendix D)  These results were captured on the 
data sheet.  The intraoperative anaesthetic record was reviewed, and 
information regarding analgesia administered intraoperatively was noted.  The 
duration of the procedure was included on the data sheet.  Patients that had a 
pain score greater than 3/10 on the VAS score received rescue analgesia in 
the form of diclofenac 1mg/kg, diluted in 250 ml of Ringer‘s lactate, over 30 
minutes IVI. 
 
The study ended because of the change in protocol at CHBAH in June 2011.  
The new protocol caused the numbers of patients presenting for EVAC or 
MVA to reduce to near  zero. 
 
1.7  Significance of the study 
 
1. The results of the study may guide anaesthetists to change currently 
accepted analgesia practice for patients presenting for EVAC. 
2. The study results may guide primary health care providers performing 
MVAs to change protocols with regard to analgesia given to these 
patients. 
3. The results may provide an estimate as to whether additional analgesia 
should be provided post-procedure for EVAC or MVA patients above 
the normally prescribed analgesia. 
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4. The study should encourage improvement of postoperative pain care in 
our hospitals.  
5. The results of the study may lead to further research in the field of 
providing analgesia and management of postoperative pain for patients 
presenting for EVAC and MVA. 
 
1.8  Limitations 
 
1. Both TOP and post-miscarriage patients were included.  This was done 
because these patients present as one group to the anaesthetist.  
However, this may have resulted in heterogeneity in the group. 
2. Patients may have varying degrees of emotional strain owing to the 
nature of the circumstances in which they present.  Emotion may alter 
the perception of pain, and thus create a bias. 
3. Study period:   
Data was collected until the protocol change in June 2011.  Data was     
collected at times convenient to the investigator, as per departmental 
roster allocations.  
4. Surgeon and anaesthetist variation:    
EVAC is performed using a standardised technique taught at CHBAH.  
However, the EVACs were perfomed by different surgeons and 
anaesthetists, with different levels of experience and with differing 
surgical durations.  The impact on the study will be discussed in 
chapter 5. 
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5. Contextuality: 
This study was done in the context of patients presenting for EVAC or 
MVA at CHBAH.  Generalisation to other populations may be limited. 
6. Retrospective review of data: 
Data collected from the anaesthetic chart was done retrospectively, as 
with all retrospectively collected data, the quality of the data collected is 
dependent on the quality of record keeping. 
 
1.9  Research report outline 
 
This research report will comprise the following chapters: 
Chapter One:    an introduction to the study, including the aim and 
objectives of the study, and a brief summary of the 
methodology used. 
Chapter Two: a literature review pertaining to the topics raised by the 
study. 
Chapter Three: a detailed description of the methodology used for the 
study. 
Chapter Four: the results of the study. 
Chapter Five: an interpretation of the results of the study, and a 
discussion of the issues raised by the results. 
Chapter Six: a summary of the study, and conclusions drawn from the 
study. 
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CHAPTER 2 - LITERATURE REVIEW 
 
In this chapter different literature applicable to the two procedures will be 
reviewed and discussed.  Pain management for the two procedures will be 
reviewed.   
2.1  Introduction 
 
MVA and EVAC are common minor gynaecological procedures performed 
worldwide.  
 
Early pregnancy failure occurs in 14 – 19% of recognised pregnancies.  (3) 
No statistics on the incidence of miscarriages for South Africa could be found. 
Statistics on legal TOP in 2003 looking at 60 countries, found that the 
incidence of abortions for large countries like the United States were more 
than a million for 2003.  (12)   
 
The same study found TOP rates for South Africa in 1997 to be 0.6%.  (12).  
The reported number of TOPs for 2010 were 68 736.  (13)    
 
2.2  Description of EVAC 
 
EVACs were first performed in the late 19th century.  EVAC is a procedure 
done under general anaesthetic, where the contents of the uterus are 
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removed following, for example, a miscarriage.  The products of conception 
are removed from the uterus with a curette.  (14)   
 
2.2.1  Indications 
EVACs are commonly performed to resolve abnormal uterine bleeding, to 
remove retained products of conception after miscarriage, or for TOP and for 
management of molar pregnancies.  (1)   
 
EVACs done under general anaesthesia are usually done when the 
gestational age is more than 14 weeks.  (2) (4) 
 
2.2.2  Contra-indications 
A relative contra-indication for performing an EVAC under general 
anaesthesia would be, for example if the patient is considered as having a full 
stomach for whatever reason.  In this case the procedure could still be 
performed, but rather under regional anaesthesia.  (15) 
 
2.2.3  Technique 
EVACs are performed under general anaesthesia. General anaesthesia 
usually comprises the administration of a combination of propofol, alfentanil 
and anaesthetic vapour (such as isoflurane or halothane and nitrous oxide or 
air in oxygen).  (16) 
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The patient lies in the dorsal lithotomy position.  An iodine solution is used to 
clean the perineum and vagina.  A bimanual examination is performed to 
study the adnexa and to determine the size, shape, consistency, and position 
of the uterus.  A full bladder may interfere with the determination of the uterine 
position, so catheterization of the bladder may be necessary.  Knowing the 
position of the uterus minimizes the chance of perforation of the uterus.  (15) 
 
The vagina is retracted with a weighted vaginal speculum in order to visualize 
the cervix.  The surgeon performs the uterine curettage by first dilating the 
cevical os if needed, then clamping the anterior lip of the cervix.  This aligns 
the cervix and the uterus in the same axis to decrease the risk of perforating 
the uterus.  A uterine sound is used to measure the depth of the uterine 
cavity.  (15)           
 
The products of conception are removed using a series of sharp curettes of 
different sizes that are inserted through the cervical os.  The surgeon then 
uses these to scrape the walls of the uterine cavity.  (15)    
 
2.2.4  Complications 
A review of 14 903 cases of surgical TOP found the most common 
complications to be retention of products (2%), bleeding from clamping the 
cervix (2%), infection (< 1%) and perforation of the uterus (0.05%).  (17) 
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Other complications mentioned by the World Health Organization are trauma 
to the cervix, and also anaesthetic complications such as cardiorespiratory 
depression and toxicity of local anaesthetics.  (2) 
 
2.3  Description of MVA 
 
The use of vacuum aspiration to remove uterine contents was pioneered in 
1958 by Drs Yuantai Wu and Xianzhen Wu in China, but their paper was only 
translated into English 50 years later.  (18)  Dorothea Kerslake introduced the 
method into the United Kingdom in 1967, and also published a study in the 
United States.  Harvey Karnen refined the technique in the early 1970‘s, and 
developed a soft, flexible cannula that reduced the risk of perforating the 
uterus.  (18) 
 
MVA uses aspiration to remove the contents of the uterus through the cervix.  
It is a method of induced abortion as well as a therapeutic procedure used 
after miscarriage.  (18)   
 
2.3.1  Indications 
Indications for performing a MVA include TOP and management of 
miscarriage.  MVA under conscious sedation, with or without local 
anaesthesia, is usually done when the gestational age is less than 14 weeks 
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and the patient is haemodynamically stable (i.e. not requiring initial 
resuscitation).  (1)   
2.3.2  Contra-indications 
Contra-indications to performing a MVA occur when the gestational age is 
more than 13 weeks, or where haemodynamic instability is present.  (2) 
 
2.3.3  Technique 
MVA can be performed under conscious sedation, with or without a 
paracervical block using local anaesthesia.  Normally, patients receive 
intramuscular diclofenac before the procedure for prevention of pain.  (1)  
MVA is performed by inserting a cannula with a hollow suction tip, connected 
to a syringe, into the cervical os.  A vacuum then extracts the products of 
conception, as the suction tip is rotated gently around the uterus.  (19) 
 
2.3.4  Complications 
Complications that can arise from MVA, include bleeding from the uterine 
tissue or cervix, retained products and trauma to the cervix and uterus.  The 
risk of perforating the uterus from MVA is minimal.   (2) (17) 
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2.4  Pain 
 
Management of perioperative pain is an important part of patient care for the 
anaesthesiologist.  Pain is an individual acute sensation and requires specific 
care as it results in suffering, systemic complications, prolonged treatment 
and increased hospitalization costs.  (3) 
 
The subjective character of pain, and the complexity of the emotion that is 
evoked, make its reliable measurement by health care professionals a key 
factor in its successful management.  (20) 
 
2.4.1  Causes of pain from EVAC and MVA 
Even though MVA or EVAC are brief procedures lasting 5–10 min, 97% of 
women experience pain during the procedure.  (1)   
 
The pain of EVAC and MVA is a combination of pain due to cervical dilatation, 
and of pain due to uterine contractions. The cervix and lower uterine segment 
are innervated by parasympathetic fibers from S2 to S4, which form ganglia 
lateral to the cervix and enter along with the uterine blood vessels.  (7)  
 
The fundus is innervated by two groups of nerve fibres:   
- sympathetic fibres from T10 to L1 via the inferior hypogastric nerve, 
which enter the uterus at the uterosacral ligaments, and  
- ovarian plexuses which enter at the cornua.  (7)   
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Pain sensation transmits via somatic sensory and sympathetic pathways from 
the posterolateral aspect of the cervix to the lateral spinothalamic tracts of the 
spinal cord.  (7) 
 
Pain after TOP is usually described as abdominal cramps, similar to those 
experienced during dysmenorrhoea.  It has been postulated that this kind of 
pain may be related to prostaglandin release, which produces painful 
contractions of the myosalpinx and the myometrium.  (21)  Non-steroidal anti-
inflammatories have been shown to be more effective than paracetamol in 
controlling this type of pain.  (21) 
 
2.4.2  Standard procedure for management of pain from EVAC 
Short acting opioids, such as alfentanil, are the most effective intraoperative 
analgesic to use for a short procedure such as EVAC.  Use of a short acting 
opioid decreases the incidence and severity of side-effects, ensuring that 
patients recover quicker, yet still ensuring postoperative analgesia.  Side 
effects of opioids may include nausea and vomiting, pruritis, respiratory 
depression and sedation.  (9) 
 
In a study comparing medical versus surgical TOP, 242 women who 
underwent surgical TOP, were given either diclofenac 100 mg rectally, or 
paracetamol 1000 mg rectally, in theatre following the procedure.  (22)   
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However, a further 96 (39.7%) women required additional analgesia, with 91 
(37.6%) women requesting oral analgesia and 5 (2.1%) requesting parenteral 
opioids.  (22)  Using only simple analgesics like paracetamol and diclofenac 
for EVAC may not be enough to ensure optimal postoperative analgesia.  (11) 
 
A Swedish study completed in patients undergoing EVAC under general 
anaesthesia with propofol and fentanyl, found no beneficial effect of 
administering paracetamol 1 g rectally at the end of surgery.  The majority of 
patients still experienced mild to moderate pain.  (21) 
 
One study investigating patients undergoing EVAC due to second trimester 
abortion, found 34% of patients still experienced severe pain.  The study does 
not mention at which times postoperatively this pain was reported.  No 
mention is made of which analgesia was given.  (23) 
 
Standard procedure at CHBAH for EVAC, is to use alfentanil intraoperatively 
for pain relief and a combination of paracetamol and ibuprofen orally 
postoperatively.  Additional combinations of ketamine and diclofenac, may 
also be used.      
 
2.4.3  Standard procedure for management of MVA 
In a study looking at MVA for first trimester pregnancy loss, patients were 
given 100 mg diclofenac rectally, and then randomly received either 
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remifentanil and midazolam, or remifentanil and propofol during the 
procedure.  (24)   
 
In this study low pain scores and high acceptability of MVA by all women were 
found, regardless of the technique used for the administration of analgesia.  
None of the women needed additional postoperative pain relief and all were 
discharged within three hours following the procedure.  (24)  
 
Gazvani et al investigated ibuprofen and tramadol as adjuncts to pain relief in 
manual vacuum aspirations done under local anaesthesia.  In this study, there 
was no significant difference in effect between the two drugs immediately 
postoperatively.  They found that ibuprofen was more effective than tramadol 
in reducing pain 30 minutes following the procedure.  (25) 
 
Literature from South Africa is limited. One study done at King Edward VIII 
Hospital in Durban examined pain relief for patients undergoing TOP under 
MVA.  In this study, diclofenac intramuscularly was prescribed 30 minutes 
prior to the MVA.  It was found that a significant number of patients still 
experienced pain during and after the procedure.  (19) 
 
Standard procedure at CHBAH for MVA is to give diclofenac 75 mg IMI 20 
minutes prior to the procedure.  
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2.4.4  Pain measurement tools 
The sensory or discriminative component of pain has been quantified primarily 
through psychophysical methods that attempt to establish a threshold for pain 
and through rating scale methods.  The measured variable is generally the 
severity or intensity of pain.  (20) 
 
A range of interpretations of pain have led to the development of various 
measurement tools that address different components of pain.   
Most of the commonly used methods to measure pain can be viewed as rating 
scales, including:   
 
-  The Verbal Descriptor / Rater Scale,  
-  The Numerical Rating Scale and  
-  The Visual Analogue Scale (VAS).  (20) 
 
The Verbal Descriptor Scale was devised by Keele in 1948, and is based on 
words numerically ranked such as ‗none‘, ‗slight‘, ‗mild‘, ‗moderate‘ or  
‗severe‘.  This was used to assess responses to analgesia over a 24 hour 
period.  (20)   
 
Downie described the numerical rating scale in 1978 as either a horizontal or 
vertical line with ‗0‘, indicating no pain, located at the bottom or one extremity 
and ‗10‘, indicating severe pain at the top or the other.  Currently there are 
multiple versions of this scale.  (20) 
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The VAS was first developed over 70 years ago, and is possibly the most 
widely used assessment tool in the measurement of pain.  During its early 
years, the VAS was popular for measuring subjective phenomena.  Two of the 
leading advocates of this method were Clarke and Spear in 1964, and 
Huskisson in 1974.  The latter used a VAS to measure intensity of pain.  (20) 
 
The VAS is a simple and frequently used method for evaluting variations in 
pain intensity.  (24)  The VAS consists of a 10 cm line anchored by two 
extremes of pain with the left side representing ‗no pain‘ and the other end 
representing ‗unbearable pain‘.  Patients are asked to make a mark on the 
line that represents their level of perceived pain intensity.  (5) (20)  Figure 2.1 
 
No pain ------------------------------------Moderate  --------------------------- Most severe pain 
0                                                         5                                                   10 
 
 Figure 2.1 Visual analogue scale (6) 
 
The VAS is recommended as a research tool, based on its methodological 
qualities of reliability, validity, sensitivity and appropriateness for a day 
surgery population.  It is also one of the most widely used assessment tools 
for postoperative pain.  (20) 
 
In the Departments of Anaesthesiology at Johns Hopkins Bayview Medical 
Center, Baltimore and Vanderbilt Medical Center, Nashville, research was 
done to determine whether the VAS can be used to accurately measure pain 
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in the immediate postoperative period in order to compare the effect of 
different analgesic regimens.  (26) 
 
The study concluded that the VAS seems to be a valid measure of pain in the 
immediate postoperative period.  It is easily understood, but has some 
limitations.  Any single VAS measurement should be considered as accurate 
± 20 mm.  In using the VAS for treatment decisions or for the measurement of 
the effect of pharmacological interventions, one needs to be aware of this 
imprecision.  (26)  Another limitation of the VAS is that it only measures pain 
intensity, or the sensory aspects of pain.  (6)   
 
The use of the VAS as a pain measurement tool benefits the respondent, as it 
uses few words and, therefore, vocabulary is less of an issue.  Provided that 
clear instructions are given to respondents, it is reasonably simple to 
complete.  (20) 
 
Using the VAS to determine the amount of pain experienced  was found to be 
easy and brief to administer and score, and it is a good method of expressing 
pain severity.  Because is has the properties of a ratio scale, it has a true zero 
point and, thus, differences between VAS measurements can be interpreted 
as meaningful percentages.  The VAS has a continous frequency distribution, 
which allows statistical tests to be conducted on average pain levels.  (20)  
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The VAS was found to be methodologically sound, conceptually simple, easy 
to administer and unobtrusive to the respondent.  The VAS seems to be most 
suitable for measuring intensity of pain after day surgery.  (20) 
 
The VAS is a well studied method for measuring both acute and chronic pain, 
and its usefulness has been validated by several investigators.  (5) (26) 
 
The purpose of this study, is to investigate the intensity of pain in the 
postoperative period in the two groups of patients.  This makes the VAS ideal 
to use as a measuring tool of pain in this study. 
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CHAPTER 3 – METHODOLOGY 
 
In this chapter the methodology that was followed will be outlined and 
discussed. 
  
3.1  Study design 
 
This study was a prospective observational study. 
Prospective: The patients were followed forward in time until the 
required data was collected. 
Observational: The data was collected without any intention of 
intervention in the gynaecological and anaesthetic 
management of the participants.  Rescue analgesia was 
provided in line with ward protocols. 
 
The study design chosen will provide an appropriate method to determine 
whether patients presenting for EVAC and MVA, experience postoperative 
pain and also the extent of the pain.  This study design will compare these. 
 
3.2  Study site 
 
The study was conducted in the gynaecology theatre reception and recovery 
room, as well as the MVA procedure recovery room in the maternity wing of 
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CHBAH, in Soweto, Johannesburg.  CHBAH is a 2800 - bed  tertiary hospital 
providing care for a population in the low-income bracket.  
 
3.3  Study population 
 
The study population consisted of women presenting for EVAC or MVA 
following TOP or incomplete miscarriage (ICA) at CHBAH. 
 
Before the protocol change in June 2011, MVAs were usually done when the 
gestational age was less than 14 weeks and the patients were 
haemodynamically stable (i.e. not requiring initial resuscitation).  EVACs were 
done under general anaesthesia for patients who were more than 14 weeks 
gestational age or if any haemodynamic instability existed. 
 
3.4  Study period 
 
Data collection was done over the period March 2009 to June 2011. The 
majority of data being collected March to May 2011. 
 
3.5  Ethical considerations 
 
This study has been approved by the University of the Witwatersrand, Human  
Research Ethics Committee.  (Appendix A) 
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The study has been approved by the Post-Graduate Committee of the  
University of the Witwatersrand, Faculty of Health Sciences. 
Permission to conduct this study has been granted by the Senior Clinical  
Executive at CHBAH.  (Appendix B) 
This study has been structured in accordance with the Declaration of Helsinki  
(last updated October 2000). 
 
3.6  Definitions 
 
1. EVAC / Dilation and curettage:  The procedure of dilating the cervix 
and removing products of conception from the uterus with a curette.  
(14) 
2. MVA:  Aspiration of the content of the uterus using a soft, flexible 
suction tip/canulla connected to a syringe or vacuum source.  (18)   
3. Pain:  an unpleasant sensory and emotional experience associated 
with actual or potential tissue damage.  (4) 
4. Postoperative period:  The time period after a surgical procedure.  In 
this study, the time immediately up to three hours after EVAC or MVA. 
(27) 
5. VAS:  The VAS is a simple and often used method for evaluting 
variations in pain intensity.  (24)  The VAS consists of a 10 cm line 
anchored by two extremes of pain with the left side representing ‗no 
pain‘ and the other end representing ‗unbearable pain‘.  Patients are 
28 
 
asked to make a mark on the line that represents their level of 
perceived pain intensity.  (5) (20)  
 
3.7  Sample population and sampling method 
 
The sample size was calculated assuming that a difference existed between 
the two groups of patients.  The total sample calculated initially was 100 
patients.  The confidence interval of 9.3 would provide a confidence level of 
95% for a population of 1000 patients. 
 
In June 2011 the protocol for managing patients for MVA‘s at CHBAH was  
changed.  These patients are no longer routinely managed at CHBAH.  All  
routine MVA patients are now being managed at primary level clinics.  Only  
complicated cases are referred for management at CHBAH.  This change in  
protocol has almost completely eliminated the numbers of patients presenting  
for MVA and EVAC at CHBAH. 
 
The study consisted of a total of 53 patients.  These patients were included in  
the study before the protocol change in June 2011.  There were 26 patients in  
the EVAC group and 27 in the MVA group.  This affected the power of the 
study and will be further discussed in Chapter 4 and 5.  
 
Consecutive convenience sampling was used.  At CHBAH there is one 
theatre for gynaecological emergencies including EVAC, and one procedure 
room for patients requiring MVA.  Patients for EVAC were approached in the 
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ward or theatre reception area awaiting EVAC for inclusion in the study.  
Patients for MVA were approached in the MVA procedure waiting room for 
inclusion in the study. 
 
The inclusion process stopped when there were a total of 53 patients as a 
result of the change in protocol at CHBAH.  Due to the sample size constraint, 
this was deemed a pilot study. 
 
3.8  Inclusion criteria 
 
ASA I and II patients presenting for EVAC or MVA at CHBAH were 
approached for inclusion in the study. 
 
3.9  Exclusion criteria  
 
The following patients were excluded from the study: 
1. Patients younger than eighteen years or otherwise unable to give  
           Informed consent. 
2. Patients other than ASA I or II. 
3. Patients that were haemodynamically unstable preoperatively, in other  
words, patients that required preoperative resuscitation with   
intravenous fluids and/or vasopressors. 
4. Patients with a conta-indication to diclofenac.     
 
30 
 
3.10  Data collection 
 
Patients that met the selection criteria were invited to participate in the study  
before having the procedure.  The aims of the study were explained, as  
well as the risks and potential benefits.  Patients received an information  
sheet containing all details of the planned study.  (Appendix C)   
 
The information sheet explained the reason for the study, the patient‘s  
involvement in the study, the right to refuse to participate without  
repercussions to their care, and the right to withdraw from the study at any  
time.  A 24-hour contact number was supplied should they have required  
further information.  The printed information was provided in English. 
 
The researcher and a translator provided verbal information in a language that  
the patient could understand if they could not understand English, or were not  
able to read the document.  Written consent was obtained from all patients  
agreeing to participate.  (Appendix D).  
 
Data was then collected from the patient history and hospital file, and post- 
procedure from the anaesthetic record, and then recorded on the data sheet.   
(Appendix E) 
 
Patients‘ names and hospital numbers were kept seperate from the data  
collection sheets, and were encoded by a numerical coding system.  This  
code was only known to the investigator.  All information that would link a  
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patient identity to the study was kept seperate and confidential. 
 
Patients were allowed to withdraw from the study at any time and no patient  
was coerced into participation in the study. 
 
3.10.1  Patient information 
Data collected was entered onto a seperate data sheet for each patient, and 
also onto a spreadsheet.   
 
The following data was collected: 
1. Patient age 
The patient‘s age was recorded in years. 
2. Gestation 
The gestational age was recorded in weeks. 
3. Type of procedure 
The type of procedure the patient was undergoing was recorded, 
whether EVAC or MVA. 
4. Reason for the procedure 
The reason for the patient presenting for either EVAC or MVA was 
noted. 
5. Analgesia received 
Any analgesia the patient received was recorded:  this included pre- 
procedure,  during the procedure and post-procedure.  
6. Duration of the procedure 
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The duration of the procedure was recorded in minutes. 
7. VAS score 
The VAS score was recorded at different intervals post-procedure:  10 
minutes, 40 minutes, 2 hours and 3 hours. This was recorded as a 
ratio. 
8. Rescue analgesia 
If the patient had a VAS score greater than 3/10, rescue analgesia was 
offered in the form of diclofenac 1mg/kg, diluted in 250 ml Ringer‘s 
lactate, over 30 minutes IVI. 
 
3.10.2  Procedure in theatre or MVA room 
The standard technique for conducting EVAC under general anaesthesia or 
doing MVA in the procedure room at CHBAH was followed.  The technique 
and drugs used during the procedure were at the discretion  of the specific 
anaesthetic registrar allocated to the gynacological emergency theatre for the 
day. 
 
Before the protocol change in June 2011, MVA‘s were done in the  
MVA room in the gynaecology departement.  Uncomplicated cases (TOP  
patients) were managed by a trained professional nursing sister.  Complicated 
cases were done by the attending gynaecology registrar.  
 
After completion of the procedure, pain scores were assessed using a VAS.   
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The VAS used was administered by the investigator.  Patients were followed 
up post-procedure in the recovery rooms or post-procedure ward.  Patients 
that had a VAS greater than 3/10 received rescue analgesia. 
   
Normal protocol for post-procedure analgesia at this hospital is paracetamol 
1g orally and ibuprofen 400 mg orally 8 hourly for 3 – 5 days post-procedure 
for both groups of patients. 
 
3.11  Data analysis 
 
The collected data was entered into a Microsoft Exel ® spreadsheet and 
analysed with Statistica ® version 10.0.  Data were presented as means and 
standard deviation, or frequencies and percentages for continuous and 
categorical variables respectively.  A Mann Whitney test was used for 
comparison of continuous variables (not normally distributed) between the two 
groups.  For comparison of categorical variables between the groups a Chi 
square or Fisher exact test (when necessary) was performed.  Differences 
between the two study groups and the level of pain overall (no pain, ≤ 3 and 
>3) was calculated using a Mantel & Haenzel Chi Square test.  Bonferroni 
correction for two by two comparisons was used.  A p-value < 0.05 was 
considered significant. 
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CHAPTER 4 - RESULTS 
 
4.1 Sample and patient refusal 
 
A total of 59 patients were approached to participate in the study, of which 
four patients refused to participate.  The patients did not state a specific 
reason for refusal.  Two patients were younger than 18 years of age.  A total 
of 53 patients were used in this study.  There were 26 patients in the EVAC 
group and 27 patients in the MVA group.   
 
4.2  Results related to characteristics of patients that 
underwent EVAC and MVA 
4.2.1  Age of patients 
The mean overall age of patients presenting for EVAC or MVA was 25.9 
years, with a standard deviation (SD) of 4.7.  In the EVAC group the youngest 
patient was 20 years and the oldest 32 years.  The mean being 25.5 years 
and SD 3.1.  The youngest patient included in this study in the MVA group 
was 18 years and the oldest 40 years.  The mean was 26.3, SD 5.8.    
See Table 4.1. 
4.2.2  Gestational age 
The mean gestational age for both groups was 12.9 weeks with SD of 4.2.  In 
the EVAC group the minimum gestational age was 13 weeks, the maximum 
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gestational age was 21 weeks.  In this group the mean gestational age was 
16.3 weeks, SD of 2.2.  In the MVA group the minimum gestational age was 2 
weeks and maximum 14 weeks, the mean was 9.6 weeks and SD 2.9.   
(Table 4.1) 
 
Table 4.1  Characteristics of patients that underwent EVAC and MVA 
Characteristics EVAC MVA P value 
 Mean±SD Mean±SD  
N 26 27  
Patient Age (years) 25.5 ± 3.1 26.3 ± 5.8 0.83 
Gestational age (w) 16.3 ± 2.2 9.6 ± 2.9 < 0.0001 
Length of procedure  
(Minutes) 26.5 ± 8.5 6.2 ± 2.8 < 0.0001 
 
Frequency 
(n, %) 
Frequency 
(n, %) 
 
Amount of analgesic 
drugs received    
0 2 (7.6%) 0 (%)  
1 11 (42.3%) 27 (100%) <0.0001 
2 13 (50%) 0 (%)  
VAS 10 0.8 ± 2.2 4.7 ± 3.5 0.0002 
Vas 40 0.8 ± 1.6 1.5 ± 1.6 0.07 
VAS 2hr 0.1 ± 0.4 0.1 ± 0.4 0.66 
VAS 3hr 0.1 ± 0.6 0.07 ± 0.2 0.49 
Pain (overall) 0.6 ± 0.7 1.4 ± 0.8 0.0007 
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4.2.3  Duration of procedure 
In the EVAC group, the shortest duration of the procedure was 15 minutes 
and the longest 50 minutes, the mean time was 26.5 minutes, SD 8.5 
minutes.  In the MVA group, the longest duration of the procedure was 15 
minutes and the shortest 2 minutes.  The mean duration of a MVA was 6.2 
minutes, SD 2.8 minutes.  (Table 4.1) 
 
4.2.4  Amount of analgesic drugs received 
50% of patients (13/26) that underwent an EVAC received two different drugs 
for analgesia, 11 patients received one drug only, and two patients in this 
group received no analgesia.   Of these two patients, one patient had a VAS 
of 1/10 at 2 hours.  The other patient reported no pain over the study period.  
Patients undergoing MVA all received one drug only, diclofenac 75 mg IMI 20 
minutes pre-procedure.  (Table 4.1) 
 
4.2.5  Reason for EVAC or MVA 
In the EVAC group 14 patients (54%) underwent the procedure for TOP.  Nine 
patients (35%) underwent EVAC following ICA, and 3 (11%) following 
intrauterine fetal deaths (IUFD).  (Figure 4.1) 
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In the MVA group 23 patients (85%) underwent the procedure for TOP and 
only 4 (15%) following ICA.  The p value was 0.02.  (Figure 4.2) 
 
TOP
14
ICA
9
IUFD
3
P=0.02
 
Figure 4.1  Reason for procedure – EVAC group 
 
TOP
23
ICA
4
P = 0.02
 
Figure 4.2  Reason for procedure – MVA group  
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4.3  Results related to the objectives 
 
4.3.1  To determine whether patients undergoing EVAC 
experience pain postoperatively, and to describe the intensity 
of postoperative pain experienced 
In the EVAC group 26 patients participated:  (Table 4.1) 
 
4.3.1.1  Pain at 10 minutes in the EVAC group 
At 10 minutes, 20 patients (76.92%) had a VAS score of 0/10.  One patient 
(3.85%) had 10/10 pain.  Two patients (7.69%) had a score of 1/10, another 
two had pain 3/10 and one patient (3.85%) had pain 5/10.  (Figure 4.3)   
The mean VAS at 10 minutes was 0.8, SD 2.2.  (Table 4.1) 
 
 
Figure 4.3 VAS at 10 minutes 
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4.3.1.2  Pain at 40 minutes in the EVAC group 
At 40 minutes 18 patients (69.23%) had 0/10 pain.  The highest pain score at 
40 minutes was 5/10, (2 patients – 7.69%).  Three patients had a VAS score 
of 1/10 (11.54%), one patient (3.85%) had 2/10 pain and two patients (7.69%) 
had a VAS score of 4/10.  (Figure 4.4)  The mean VAS at 40 minutes was 
0.8, SD 1.6.   (Table 4.1) 
 
 
Figure 4.4 VAS at 40 minutes 
 
4.3.1.3  Pain at 2 and 3 hours in the EVAC group 
At 2 and 3 hours the majority of patients had no pain (84% and 92% 
respectively).  The highest pain scores at those times were 2/10 (one patient), 
at 2 hours and 3/10 (one patient) at 3 hours.  (Figure 4.5 and 4.6)  The mean 
VAS at 2 hours was 0.1, SD 0.4, and at 3 hours the mean VAS was 0.19,  
SD 0.6.  (Table 4.1)   
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Two patients received no analgesia – their VAS scores were 0/10 except for 
one score at 3 hours of 1/10 for one of these patients. 
 
 
Figure 4.5 VAS at 2 hours 
 
 
Figure 4.6 VAS at 3 hours  
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4.3.1.4  Pain overall during study period in EVAC group 
Twelve patients (46.15%) had no pain overall during the investigative period, 
10 patients (38.46%) had pain less than or equal to 3/10, and 4 patients 
(15.38%) had pain greater than 3/10.  The p-value was < 0.017 between 
patients that had pain ≤ 3 vs pain > 3 and between no pain and pain > 3.  The 
overall p-value was 0.0007.  (Figure 4.7) 
 
 
Figure 4.7 Pain over total study period 
 
Three patients (11.54%) required rescue analgesia (in the form of diclofenac 
75 mg diluted in 250 ml Ringer‘s lactate, IVI) in the uterine evacuation group. 
 
No patients in the MVA group received rescue analgesia.  This will be 
discussed in chapter 5. 
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4.3.2  To determine whether patients undergoing MVA 
experience pain postoperatively, and to describe the intensity 
of postoperative pain experienced. 
 
The MVA group had 27 patients:  (Table 4.1) 
 
4.3.2.1  Pain at 10 minutes in the MVA group 
Seven patients (25.93%) had a VAS score of 0/10, two patients had a VAS 
score of 3/10 and less, while 14 patients (51.85%) had pain ranging from 5/10 
to 9/10.  Four patients (14.81%) had 10/10 pain.  (Figure 4.3)  The mean VAS 
at 10 minutes was 4.7,SD of 3.5.  (Table 4.1) 
 
4.3.2.2  Pain at 40 minutes in the MVA group 
At 40 minutes 11 (40.7%) patients had no pain and 12 (44.44%) patients had 
pain equal or less than 3/10.  Four patients (14.82%) had pain greater than 
3/10.  (Figure 4.4)  At 40 minutes the mean VAS was 1.5 with a SD of 1.6.  
(Table 4.1) 
 
4.3.2.3  Pain at 2 and 3 hours in the MVA group   
At 2 and 3 hours 25 patients (92%) having undergone MVA did not have any 
pain and the other two patients had pain scores of 1/10 or 2/10.  (Figure 4.5 
and 4.6)  The mean VAS at 2 hours was 0.1, SD 0.4 and at 3 hours the mean 
VAS was 0.07, with a SD 0.2.  (Table 4.1)   
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4.3.2.4  Pain overall during study period in MVA group 
Overall, 18 (66.6%) of patients in the MVA group had pain greater than 3/10, 
three out of 27 (11.1%) had pain less than or equal to 3/10, and 6 (22.2%) 
had no pain at all during the study period.  (Figure 4.7) 
 
4.4  Summary of results 
 
In this chapter the results of the study were presented.  Patients in the MVA 
group experienced significantly more pain immediately postoperatively than 
the EVAC group.  However, there were no significant differences found in pain 
experienced between the two groups at 40 minutes and after that.  
 
Due to the small sample size, an analysis of whether patient age, gestational 
age and duration of procedure had an effect on the pain experienced, was not 
feasible. 
 
Due to the sample size constraint, the statistical findings are not considered to 
be statistically proven.  This study was therefore deemed a pilot study. 
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CHAPTER FIVE – DISCUSSION 
 
Chapter 5 includes an interpretation of the results of the study, and a 
discussion of the issues raised by the results.  Chapter 5 also includes a 
discussion of the study in terms of potential limitations of the study, 
implications for clinical practice and further research. 
 
5.1  Patient refusal 
 
Four patients refused to participate.  The reasons for their refusal were not 
clearly stated.  This could possibly have been because of the possible 
emotional strain of having to undergo either a MVA or EVAC for the various 
presenting reasons.  
 
5.2  Results pertaining to the objectives of the study 
 
5.2.1  Pain in the EVAC and MVA patients 
Results from this study showed that there was a significant difference in VAS 
scores between the two groups at 10 minutes.  20/26 (76.9%) of patients in 
the EVAC group had no pain at 10 minutes, compared to the MVA group 
where only 7/27 (25.9%) had no pain at 10 minutes. 
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Two of the 26 patients in the EVAC group had pain greater than 3/10 at 10 
minutes compared to the MVA group where 18/27 patients had pain greater 
than 3/10 at 10 minutes.  In the EVAC group four of the 26 patients had pain 
equal to or less than 3/10, whereas in the MVA group two of the 27 patients 
had pain equal to or less than 3/10 at 10 minutes. 
 
Patients in the MVA group experienced significantly more pain immediately 
postoperatively (at 10 minutes) than the EVAC group.  However, there were 
no significant differences found in pain experienced between the two groups 
at 40 minutes.  At two and three hours no difference in pain experienced could 
be shown between the two groups.  This is possibly because of the small 
sample size that was used. 
 
Two patients in the EVAC group received no analgesia.  Despite this they 
reported no significant pain.  The reason for these patients not reporting 
significant pain is not clear. The literature describes the pain from an EVAC as 
abdominal cramps, similar to those experienced during dysmenorrhoea.  (21)   
 
Patients may not regard this type of pain as being significant.  These 
particular patients could have had a higher pain threshold, or the lack of pain 
could be due to under reporting of pain by patients in general.  In one cross-
sectional study from South Africa investigating second trimester abortions, 7% 
of the patients reported no pain after EVAC, although the exact timing of the 
interview is not stated.  (23)   
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The results from the EVAC group is in keeping with current literature that 
looked at intra-operative pain in this group of patients.  The literature does not 
report significant pain immediately postoperatively.  (23)   
 
Very few studies investigated pain in MVA patients.  Literature found, showed 
that patients that underwent MVA and reported no postoperative pain, had all 
received opioids and sedation during the MVA procedure.  (11) 
 
5.3  Results relating to characteristics of patients 
 
5.3.1  Age of patients 
There was no significant difference in the ages of patients between the two 
groups.   
 
5.3.2  Gestational age 
There was a difference in the gestational ages between the two groups.  The 
reason for this being, that MVA can only be done if the gestational age is less 
than 14 weeks, and EVACs are usually done after 14 weeks gestational age.  
There was no clear indication that increased gestational age increased the 
amount of pain experienced. For example,  three patients in the EVAC group 
had a gestational age of 20 weeks and above.  All of them had pain scores of 
0/10 throughout the entire study period.     
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5.3.3  Duration of procedure 
There was a difference in duration of procedure between the two groups.  An 
EVAC is usually a longer procedure, as the anaesthetic time has to be taken 
into consideration.  A longer duration of procedure did not equate to an 
increase in pain experienced.  The highest pain scores were recorded in the 
MVA group. 
 
5.3.4  Reason for procedure 
There was a difference between the two groups in the reason for presenting 
for either EVAC or MVA, most patients (85%) presenting for MVA were due to 
TOP. 
 
This correlated with the earlier gestational age of patients presenting for MVA. 
Patients for TOP generally present earlier (usually before 12 weeks) than 
patients with ICA (usually between 8 and 16 weeks). Pregnancy can be 
conclusively diagnosed at 4 to 6 weeks (28).  
 
Patients with unwanted pregnancies typically want to have a TOP as soon as 
possible.  By law, a TOP has to be done before 12 weeks gestational age 
without any specific reason necessary.  Between 13 and 20 weeks gestation, 
there has to be a medical, psychological or economical reason for TOP.  (29).   
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ICA usually occurs between 6 and 16 weeks, typically making a large 
proportion of these patients present too late for the 14 week MVA cut-off date.  
Performing an EVAC has been found to be safer than MVA after 12 – 14 
weeks gestation. (2) (23) 
 
 
5.3.5  Analgesia received in the EVAC group 
The anaesthesia and analgesia given for EVACs in this study was not 
standardised. Drugs and doses used varied, and was at the discretion of the 
attending anaesthetist.  Despite this, there were no significant differences in 
pain scores between the patients in the EVAC group. 
 
The different drugs used included:  alfentanil, diclofenac, fentanyl, ketamine 
and sufentanil.  Opioids were used alone or in conjunction with simple 
analgesics or ketamine.  There was no significant difference in the pain 
scores of these patients. The use of intravenous paracetamol for EVAC 
patients is not part of the current practice protocol at CHBAH.   
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5.4  Limitations 
 
5.4.1  Study period 
Data was collected by convenience sampling.  The majority of data was 
collected during April and May 2011, when it was possible according to 
departemental rostering.  The first few patients however, were assessed more 
sporadically.  This method of sampling is not as robust as other methods, 
which necessarily introduces a potential for selection bias. 
 
5.4.2  Protocol change and small sample size 
The protocol change in June 2011 effectively ended the study period as only 
complicated patients are now referred to CHBAH for MVA and also for EVAC.  
The number of patients presenting to CHBAH for MVA or EVAC is now 
significantly less than before.  This caused  the sample size to be small.   
 
It was deemed that the power of this study was insufficient because of the 
small sample size.  This study was therefore underpowered to show 
differences in pain at 40 minutes, 2 hours and 3 hours.  Despite the study 
being underpowered, a difference in pain experienced was shown between 
the EVAC and MVA group at 10 minutes.   
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A future study using a larger sample size and therefore increased power, 
should be done to conclusively detect differences in pain experienced 
between the two groups at 40 minutes, 2 hours and 3 hours postoperatively.  
 
5.4.3  Rescue analgesia 
Three of the 26 patients (11.54%) required rescue analgesia (in the form of 
diclofenac 75 mg, diluted in 250 ml Ringer‘s lactate over 30 minutes IVI) in the 
EVAC group.  Two of these patients reported a VAS score of 4/10 at 40 
minutes and one patient had a VAS score of 5/10 at 40 minutes.  At 2 and 3 
hours, these three patients reported no significant pain (equal or less than 
3/10).   
 
One other patient reported pain of 5/10 at 40 minutes.  This patient however 
was already receiving diclofenac 75 mg in 1 litre of Ringer‘s lactate IVI, 
 started during anaesthesia.  On follow up at 2 and 3 hours, this patient had 
VAS scores of 0/10 and 0/10. 
 
In the MVA group no patient received rescue analgesia, despite the finding 
that 18/27 patients had pain greater than 3/10 at 10 minutes.  The reason for 
this, according to the current practice at the time of the study, was that these 
patients received diclofenac 75 mg IMI before the MVA.  This was given only  
10 – 20 minutes prior to having the MVA, and the diclofenac had not yet 
reached maximal effect.   
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At 30 – 40 minutes after the MVA, only 4/27 patients had significant pain.  
Rescue analgesia was stipulated in the study protocol to be diclofenac 75 mg 
IVI or IMI.  As these patients had already received a dose only 1 hour before, 
a repeat dose could not be given.  This presented a limitation of this study, as 
effective pain control could not be obtained immediately.  However, at 2 and 3 
hours no patients from the MVA group had significant pain (VAS scores 0/10 
and 1/10). 
 
5.4.4  Analgesia received in the MVA group 
Before performing a MVA at the time of the study, current protocol for 
analgesia was diclofenac 75 mg IMI.  Using diclofenac IMI for analgesia in 
MVA is not incorrect, but the pharmacokinetics and pharmacodinamics have 
to be understood to make the use of this drug effective as an analgesic at the 
time of the procedure.  The diclofenac should be given 30 – 40 minutes before 
the MVA to have enough time to reach maximal effect before the procedure is 
done.   
 
The main reason for using diclofenac as analgesia in MVA was that these 
procedures were performed on an out patient basis, with patients usually only 
staying for an hour, provided that there were no complications like bleeding.  
For this study patients were asked to stay for three hours after the MVA to 
complete the study period.   
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The usual short period of observation post-procedure, limits the use of other 
drugs, such as opioids and sedative agents, for MVA.  These drugs potentially 
have more side effects, including respiratory depression.  Intravenous 
paracetamol is also not available for use in the MVA room. 
 
Another factor determining the protocol for analgesia provided for MVA, was 
that the MVA room had very limited recources in terms of monitoring and 
resuscitation equipment.  Oxygen and suction points were also limited.  
Consequently, no sedation or opioids could safely be administered to these 
patients.   
 
MVAs were mainly performed by trained professional nurses, and only 
complicated cases were done by the gynaecology registrar.  The training and 
scope of practice of these nurses does not include the use of sedation agents 
and opioids for day case procedures, which falls more in to the scope of 
practice of the anaesthetist.   
 
Before June 2011, the MVA service at CHBAH was provided by the 
gynaecology department.  Since then, MVAs are done at local clinics, where 
the analgesia provided may be even more limited. 
  
Since this was an observational study of current practice, this limitation 
revealed a flaw in current practice of the analgesia management of MVA 
patients.  This limitation questions whether any significant difference would 
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have been found between VAS scores at 10 minutes in both groups, had the 
MVA group received adequate analgesia early. 
 
5.4.5  Contextuality 
This study was done in the context of patients presenting for EVAC and MVA 
at CHBAH.  CHBAH is a tertiary state hospital that serves a predominantly 
low-income black population from Soweto and surrounding areas in 
Johannesburg.  It may not be possible to generalise the results of this study to 
other population groups. 
 
5.5  Recommendations 
 
The following should be implemented to minimize the amount of pain 
experienced in MVA patients : 
1. Increasing the time period between the patient receiving IMI diclofenac 
and performing the MVA, to at least 30 – 40 minutes. 
2. Consider the addition of paracetamol 1 g orally as added analgesic 
before the MVA is done.   
 
This combination may decrease the amount of pain experienced, and is a 
cheap method of providing analgesia. 
 
 
54 
 
Recommendations for EVAC patients: 
1. The use of multimodal analgesia has been shown to be the most 
effective method of ensuring good intra-operative and postoperative 
pain control in the EVAC group.  This practice should be continued. 
 
5.6  Importance of this study  
 
This study has importantly demonstrated the following: 
1. Proven that patients undergoing MVA DO experience significant pain 
requiring analgesia. 
2. A change in local practice of analgesia provided for MVA patients is 
necessary. 
3. Shown that patients undergoing EVAC do experience pain, but mostly 
not significant pain, which is easily managed with short acting opioids 
and simple analgesics. 
 
5.6.1  Areas for future studies 
This study highlighted areas where further research may be done with regards 
to pain management in the EVAC and MVA groups. 
 
This study should perhaps be viewed as a pilot study.  A study with a larger 
sample size should be done to determine whether any differences in 
experienced pain exist between the two groups at 40 minutes and beyond.   
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This study showed that the limited analgesia provided during and post-
procedure in the MVA group, led to these patients experiencing significant 
pain immediately post-procedure.  Future studies may investigate whether 
improved analgesia is being offered since the service was moved to primary 
level institutions.     
 
Another area for future study should investigate patient satisfaction with both 
procedures and analgesia received.  Questions asked should include whether 
patients would be prepared to undergo a MVA again. Patients who had 
received both MVA and EVAC procedures, could be asked which was the 
better experience.  
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CHAPTER 6 – SUMMARY AND CONCLUSIONS 
 
6.1  Summary 
  
In the previous chapter the results of the study were discussed.  Patients that 
underwent EVAC experienced significantly less pain immediately post-
operatively than the MVA patients.  The study was underpowered and 
therefore could not show significant differences in pain between the two 
groups at 40 minutes, 2 and 3 hours.   
 
There were differences between the two groups pertaining to reasons for the 
procedure, duration of the procedure and gestational age.   
 
This study highlighted the limitations in analgesia provided to patients 
presenting for  MVA. 
 
6.2  Conclusions 
 
This study demonstrated that EVAC patients do not experience significant 
pain postoperatively because current management, using multimodal 
analgesia, is effective in controlling pain in this group of patients. 
 
The care provided to MVA patients needs revising in terms of choice and 
timing of analgesia administration.  This service was previously offered at 
CHBAH and is currently offered at local clinics.  The analgesia provided and 
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the satisfaction of patients undergoing MVAs in the local clinics should be 
investigated, and is a potential area for future research. 
 
The results of this study have provided useful information which can be 
applied directly in the clinical setting, hopefully improving the care given to 
patients presenting for EVAC and MVA at CHBAH in the future.  
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APPENDIX B  Permission from Hospital Senior Executive 
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APPENDIX C  Patient information sheet 
 
INFORMATION FOR STUDY PARTICIPANTS 
 
Good morning. My name is Dr Mostert. I am a doctor in the Department of 
Anaesthesia of this hospital.  I would appreciate it if you could help me with a 
study I am doing, and would like to invite you to first listen to the information I 
have about the study, and then you can decide whether you would like to 
participate or not.   
 
The procedure you are going to have is clean out your womb and to stop any 
bleeding.  
 
This will either be done while you are awake or you will go theatre for a 
general aneasthetic (where you will be made asleep).  Your doctor will decide 
which of the 2 procedures you will be having.   
 
You will receive pain medication while the procedure is done.   
 
The purpose of the study I am doing is to find out whether patients like 
yourself, having this procedure, experience any pain, and how much, after the 
procedure is done.  This will help us, as doctors, to make sure we help 
patients not to have any pain during and after these procedures. 
 
There will be no risks involved for yourself if you decide to take part in the 
study, as I will only be assessing if you have pain at all after you had the 
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procedure.  If you do experiece the discomfort of pain after the procedure, 
pain medication will be given to you.   
 
The potential benefit of your participation in the study would be that you would 
be monitored for pain and would not be left in pain after the procedure.   
 
If you agree to take part in the study, then I can assess the degree of pain 
after the procedure is done.  This will be done at different times:  10 minutes, 
40 minutes, 2 hours and 3 hours after the procedure.   
 
To help you in telling me if you have pain and how bad the pain is, I will use a 
pain scale,  called a visual analogue scale.  This is tell me how you 
experience pain.  This is what the scale looks like:  
 
Visual analogue scale 
No pain ------------------------------------Moderate  --------------------------- Most severe pain 
0                                                         5                                                   10 
  
If you agree to partake in the study some of your information need to be used, 
but your name and hospital number would be kept seperate from the rest of 
the information.  The information will be collected according to a secret code 
that will only I will know.  If you consent to take part, your age, how far you 
were pregnant and all the medication you receive for pain and what type of 
procedure you have had will need to be used for the study.  All your 
information will be kept confidential. 
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If you decide not to participate in the study the procedure will continue and it 
will not affect the standard of care that you will receive.   
 
Your participation in this study is entirely voluntary.  If you decide to 
participate in the study, but change your mind at a later stage, we will remove 
all your information from the study.  
  
This clinical study protocol has been submitted to the University of the 
Witwatersrand, Human Research Ethics Committee (HREC), and written 
approval has been granted by that committee. 
 
Before you decide whether you will participate or not, do you have any 
questions ? 
 
If you want to contact me at a later stage about anything you are not sure of 
regarding the study, I am available at 076 421 0277. 
 
Thank you 
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APPENDIX D  Informed Consent Form 
 
I, _______________________________________, agree to participate in the 
study that Dr Mostert has explained to me.  
 
I understand that after I have had my womb cleared out the doctor will be 
asking me if I am having any pain and how bad it is or not.  I understand that 
this will be done at a few different times after the procedure.  I understand that 
if I am in pain I will be given something for the pain.  
 
I understand that some of my information will be used for the study:  my age, 
how far pregnant I had been, any pain medication that I receive, the amount 
of pain I feel and the type of procedure I have had. 
 
I understand that all my information will be given a special code so that no 
one will be able to trace it back to me.  I understand that my name and 
hospital number will be kept separate from my information, and will be locked 
away.  
 
I understand that my participation is entirely voluntary and that I can pull out at 
any time. 
 
Signed at _______________________ on____________________________ 
 
_____________________ 
SIGNATURE 
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APPENDIX E  Data Collection Sheet 
 
Patient data sheet 
 
Age:   
Gestation: 
Type of procedure: 
Reason for procedure: 
Analgesia received preoperatively: 
Analgesia received intraoperatively: 
Analgesia received postoperatively: 
Visual analogue score:   Actual time and ratio score: 
During recovery (10 minutes)  _________________ 
40 min     _________________ 
2 hours     _________________ 
3 hours     _________________ 
 
Rescue analgesia received: 
 
Visual analogue scale 
No pain ------------------------------------Moderate  --------------------------- Most severe pain 
0                                                         5                                                   10 
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